Study on Therapeutic Effects of Ermiao Pill and Ermiao Pill Categorized Formula in Hyperuricemic Rats Using Spectroscopic Methods
CHEN Wei-jia1, WU Yi1, XU Chen2, LIU Shu2, WANG Wen-zhe3, SONG Feng-rui2, LIU Zhong-ying1*, LIU Zhi-qiang2
1. Jilin University, Changchun 130021, China 2. Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun Center of Mass Spectrometry, Key Laboratory of Chinese Medicine Chemistry and Mass Spectrometry, Changchun 130022, China 3. Jilin Entry-Exit Inspection and Quarantine Bureau, Changchun 130062, China
Abstract：A stable mouse model of hyperuricemia was established by intraperitoneal injection of xanthine and oxonate, comparing the water extracts (containing crude drug 360 mg·mL-1) of Ermiao pill categorized formula (The ratio of atractylodes lancea to cortex phellodendri was 1∶1, 1∶2 and 2∶1, respectively) and Ermiao pill (360 mg·mL-1) administered to different groups of animals continuously for two weeks and assessing the protection or treatment of drug on hyperuricemia. The xanthine oxidase (XOD) activities in serum and liver were detected by ultraviolet-visible spectroscopy at 570 nm wavelength, The results showed that as compared with each group, the XOD activity of the model group was significantly increased in serum (p<0.01), XOD activity showed no significant difference in liver (p>0.05), but compared with the model group, the XOD activity of each treatment group was significantly lower in serum and liver (p<0.01), especially for the group treated with Ermiao pill categorized formula with the ratio of Atractylodes lancea to Cortex Phellodendri being 1∶2. The morphological changes of glomerular and tubular interstitial fibrosis were measured by Hematoxylin-eosin staining (HE staining) and Masson trichrome staining (Masson staining)for kidney paraffin sections. The results showed that the glomerular atrophy, vascular loops confusion, a certain degree of inflammatory cell infiltration, interstitial fibrosis and other phenomena appeared in the model group. Compared to model group, these pathological phenomena of the treatment groups were significantly improved. The area showed that compared with each group, the fibrosis of the model group was significantly increased (p<0.01 or p<0.05), but compared with Ermiao pill categorized formula, the differences for the group of Ermiao pill was lower (p<0.01), especially for the group treated with Ermiao pill categorized formula with the ratio of Atractylodes lancea to Cortex Phellodendri being 1∶2. In this experiment, the damage of kidney and XOD activity serve as the index to evaluate the protection or treatment of drug on hyperuricemia, providing a scientific basis for the development of Ermiao pill categorized formula.
陈维佳1，武 毅1，徐 晨2，刘 舒2，王文哲3，宋凤瑞2，刘忠英1*, 刘志强2. 紫外可见光谱及成像方法研究二妙丸药物对高尿酸血症疗效的影响 [J]. 光谱学与光谱分析, 2015, 35(04): 956-960.
CHEN Wei-jia1, WU Yi1, XU Chen2, LIU Shu2, WANG Wen-zhe3, SONG Feng-rui2, LIU Zhong-ying1*, LIU Zhi-qiang2. Study on Therapeutic Effects of Ermiao Pill and Ermiao Pill Categorized Formula in Hyperuricemic Rats Using Spectroscopic Methods. SPECTROSCOPY AND SPECTRAL ANALYSIS, 2015, 35(04): 956-960.
[1] Liu Yong, Tan Ning, Chen Jiyan, et al. Clinics, 2013, 68(1): 19. [2] Li C, Hsieh M C, Chang S J. Curr. Opin. Rheumatol., 2013, 25(2): 210. [3] Falasca G F. Metabolic diseases: gout. Clin. Dermatol., 2006, 24(6): 498. [4] Lü Yao-zhong, HU Qing-hua，WANG Xing, et al(吕耀中, 胡庆华, 王 星). Chinese Traditional and Herbal Drugs(中草药), 2010, 41(3)：418. [5] Wang Xing, Wang Caiping, Hu Qinghua, et al. Journal of Ethnopharmacology, 2010, 128(1): 107. [6] Huang Jingqun, Wang Siwang, Zhua Miaozhang, et al. Food and Chemical Toxicology, 2011, 49(9): 1943. [7] Hiroshi Akasaka, Hideaki Yoshida, Hideki Takizawa, et al. Nephrol Dial Transplant, 2014, 29(10): 1932. [8] PAN Zhi, DUAN Fu-jin, WANG Ying-hang, et al(潘 志，段富津，王颖航, 等). Li Shi Zhen Medicine And Materia Medica Research(时珍国医国药), 2008, 19(1): 112. [9] LIAN Lian, JIA Tian-zhu(廉 莲，贾天柱). Journal of Anhui Agri.(安徽农业科学), 2011, 39(15): 8911. [10] ZHOU Ling, SUN Zhao-shu, DOU De-qiang, et al(周 凌，孙兆姝，窦德强，等). Journal of Chinese Medicinal Materials(中药材), 2010, 33(2): 246. [11] McNearney T, Baethge B A, Cao S, et al. Clin. Exp. Immunol., 2004, 137(3): 621. [12] QIU Mo-yan, JIANG-Yue, ZHAO Zong-jiang, et al(邱模炎，姜 岳，赵宗江，等). Chinese Journal of Experimental Traditional Medical Formulae(中国实验方剂学杂志), 2010, 16(17): 177.
